Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling

Abstract

BackgroundCell migration and invasion are essential processes for metastatic dissemination of cancer cells. Significant progress has been made in developing new therapies against oncogenic signaling to eliminate cancer cells and shrink tumors. However, inherent heterogeneity and treatment-induced adaptation to drugs commonly enable subsets of cancer cells to survive therapy. In addition to local recurrence, these cells escape a primary tumor and migrate through the stroma to access the circulation and metastasize to different organs, leading to an incurable disease. As such, therapeutics that block migration and invasion of cancer cells may inhibit or reduce metastasis and significantly improve cancer therapy. This is particularly more important for cancers, such as triple negative breast cancer, that currently lack targeted drugs.MethodsWe used cell migration, 3D invasion, zebrafish metastasis model, and phosphorylation analysis of 43 protein kinases in nine triple negative breast cancer (TNBC) cell lines to study effects of fisetin and quercetin on inhibition of TNBC cell migration, invasion, and metastasis.ResultsFisetin and quercetin were highly effective against migration of all nine TNBC cell lines with up to 76 and 74% inhibitory effects, respectively. In addition, treatments significantly reduced 3D invasion of highly motile TNBC cells from spheroids into a collagen matrix and their metastasis in vivo. Fisetin and quercetin commonly targeted different components and substrates of the oncogenic PI3K/AKT pathway and significantly reduced their activities. Additionally, both compounds disrupted activities of several protein kinases in MAPK and STAT pathways. We used molecular inhibitors specific to these signaling proteins to establish the migration-inhibitory role of the two phytochemicals against TNBC cells.ConclusionsWe established that fisetin and quercetin potently inhibit migration of metastatic TNBC cells by interfering with activities of oncogenic protein kinases in multiple pathways.

<p>Quercetin Inhibits Adenomyosis by Attenuating Cell Proliferation, Migration and Invasion of Ectopic Endometrial Stromal Cells</p>

“…28,29 A growing number of evidences have revealed the suppressive role of quercetin on the metastatic abilities of multiple cancer cells, such as prostate, 30 oral, 31 lung, 32 liver, 33 and breast cancers. 34 Similar to these results in human cancer cells, our study also demonstrated that quercetin significantly decreased the migratory and invasive abilities in both EuESCs and EESCs in a dose-dependent manner, and this inhibitory effect was also higher in EESCs group compared to that in EuESC group. It is well known that several molecules such as Fascin, Erzin, MMP-2 and MMP-9 are critically involved in cell migration and invasion.…”

Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights

“…Due to the notable aggressive behaviour of TNBC, existing treatment options have limited or no efficacy against tumour metastasis 44,47 . Recently, Different molecular studies have allowed for the emergence of targeted therapies 48 , whereas others have evolved to explain mechanisms of resistance [49][50][51][52][53] .…”

<p>Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer</p>

“… 67 While this is a huge success for the approximately 5% of patients with mCRC who are dMMR/MSI-H, immunotherapeutic options are still lacking for patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) mCRC. 68 , 69 …”

“…It’s been proposed that VEGF inhibitors may enhance lymphocyte activation by reducing tumor-associated macrophages and regulatory T cells which typically block lymphocyte activation. 69 , 70 Therefore, by blocking the VEGF pathway, sensitivity to immunotherapy may be restored in pMMR/MSS tumors. 69 The REGONIVO and REGOMUNE trials both examined regorafenib in combination with a checkpoint inhibitor, and both had promising ORR >30%.…”